4D Molecular Therapeutics Inc

CEO Kirn David’s 750k option buy signals confidence; track vesting, clinical milestones, and dilution to gauge future biotech stock upside.

Insider option buys at 4D Molecular Therapeutics signal confidence despite volatile price, showing executives betting on long‑term value and a promising biotech pipeline.

Insider trades at 4D Molecular Therapeutics reveal disciplined, non‑discretionary activity, suggesting confidence amid a strategic pause and potential buying opportunity.

Senior director SBLENDORIO GLENN’s 45,000‑share option award at 4D Molecular signals long‑term confidence in the biotech’s pipeline, but investors should watch clinical milestones before betting on potential upside.